NasdaqGM:HELPPharmaceuticals
How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative
Cybin’s subsidiary Helus Pharma recently saw Executive Chairman and Co‑founder Eric So re‑assume the role of Interim CEO after the board requested Michael Cola’s departure, while also adding neuroscience veteran Dr. Ken Kramer as Senior Vice President of Medical Affairs.
This combination of a board-driven leadership change and a high-profile medical affairs hire could influence how investors assess Helus’ execution capabilities within Cybin’s broader clinical platform.
We’ll now examine how...